Cardio Diagnostics Holdings, Inc. (CDIOW) Stock Price & Analysis
Cardio Diagnostics Holdings, Inc. (CDIOW) rose 0.00% to USD 0.02 as of June 10, 2026 at 15:40 UTC, according to Nexqual real-time market data.
CDIOW last closed at USD 0.02; the session ranged USD 0.02–0.02 on volume of 624 shares. Market capitalization is —, with a 52-week range of USD 0.02–0.02 (NCM). Source: Nexqual, June 10, 2026 at 15:40 UTC.
Key Statistics (as of June 10, 2026 at 15:40 UTC)
| Price | USD 0.02 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.02 |
| Open | USD 0.02 |
| Day Range | USD 0.02 – 0.02 |
| 52-Week Range | USD 0.02 – 0.02 |
| Volume | 624 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CDIOW)
Nexqual's technical model rates CDIOW "BUY" based on 4 bullish and 2 bearish signals across 66 daily candles, as of June 10, 2026 at 15:40 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0.03) |
| MACD | 0 (negative) |
Analyst Ratings (CDIOW)
Wall Street analysts rate CDIOW "None", per Nexqual as of June 10, 2026 at 15:40 UTC.
| Consensus Rating | None |
|---|
Earnings (CDIOW)
Source: Nexqual, June 10, 2026 at 15:40 UTC.
Financials & Fundamentals (CDIOW)
| Total Revenue | $16,565 |
|---|---|
| Revenue Growth (YoY) | +185.10% |
| Gross Margin | +100.00% |
| Operating Margin | -66598.40% |
| Profit Margin | +0.00% |
| ROE | -65.59% |
| Debt / Equity | 5.99 |
| Current Ratio | 15.76 |
| Total Cash | $7.08M |
| Total Debt | $533,002 |
| Free Cash Flow | $-3.93M |
Source: Nexqual, June 10, 2026 at 15:40 UTC.
Financial Health Score (CDIOW)
Nexqual rates Cardio Diagnostics Holdings, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 15:40 UTC.
| Growth | Strong — Revenue +104% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $7M cash, no debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -66%, ROA -38.0% |
Ownership (CDIOW)
| Float | 2.83M |
|---|
Source: Nexqual, June 10, 2026 at 15:40 UTC.
Leadership (CDIOW)
Cardio Diagnostics Holdings, Inc. is led by Meeshanthini V. Dogan (age 36), Co-Founder, CEO & Director, per Nexqual as of June 10, 2026 at 15:40 UTC.
| Co-Founder, CEO & Director | Meeshanthini V. Dogan (age 36) |
|---|---|
| CFO & Principal Accounting Officer | Elisa Michael Luqman Esq. (age 61) |
| Chief Technology Officer | Timur Dogan (age 36) |
| Co-Founder, Chief Medical Officer & Director | Robert A. Philibert (age 63) |
Major Backers & Investors (CDIOW)
Notable institutional backers of Cardio Diagnostics Holdings, Inc. include Saba Capital Management, L.P., Clear Street Group Inc., Context Capital Management, LLC, according to Nexqual as of June 10, 2026 at 15:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Saba Capital Management, L.P. | 6.76% |
| Clear Street Group Inc. | 2.53% |
| Context Capital Management, LLC | 2.51% |
| Shaw D.E. & Co., Inc. | 2.3% |
| Boothbay Fund Management, LLC | 1.86% |
| Virtu Financial LLC | 0.95% |
| UBS Group AG | 0.17% |
Source: Nexqual, June 10, 2026 at 15:40 UTC.
From Cardio Diagnostics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
- The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management.
- It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
- It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.9 | ▼ 4.52% |
| ICUCW | SeaStar Medical Holding Corporation | USD 0.02 | ▼ 50% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 24.18% |
| HUBCW | Hub Cyber Security Ltd. Warrant | USD 0.02 | ▲ 67.01% |
| CELUW | Celularity Inc. | USD 0 | ▼ 51.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:40 UTC. This page is informational and not investment advice.